Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 14, Pages -Publisher
MDPI
DOI: 10.3390/ijms23147821
Keywords
hereditary diffuse gastric cancer (HDGC); CDH1 germline mutation; CTNNA1 mutation; molecular genetics
Ask authors/readers for more resources
This article presents an overview of the genetic characteristics and current treatment approaches of hereditary diffuse gastric cancer (HDGC). It highlights the importance of the CTNNA1 gene, among others, in relation to this disease, and emphasizes the need for risk management in diagnosing patients through genetic testing.
Hereditary diffuse gastric cancer is an autosomal dominant syndrome characterized by a high prevalence of diffuse gastric cancer and lobular breast cancer. It is caused by inactivating mutations in the tumor suppressor gene CDH1. Genetic testing technologies have become more efficient over the years, also enabling the discovery of other susceptibility genes for gastric cancer, such as CTNNA1 among the most important genes. The diagnosis of pathogenic variant carriers with an increased risk of developing gastric cancer is a selection process involving a multidisciplinary team. To achieve optimal long-term results, it requires shared decision-making in risk management. In this review, we present a synopsis of the molecular changes and current therapeutic approaches in HDGC based on the current literature.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available